Hopkins University is the number 1 university recipient of NIH funding in the United States.
Featured Startups and Technologies
Amplimmune is a product driven company that is developing immune-based biologics to treat patients in the areas of cancer, autoimmunity, transplantation and infectious diseases. Amplimmune’s scientific founders from Johns Hopkins University have identified several key immunological ligands and receptors. These immunomodulatory molecules are the basis for developing a new class of biological treatments which modulate critical mechanisms in the body’s immune system with the aim of bettering the lives of patients suffering from aberrant immunological conditions.
Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs. Worldwide leaders in the development of a proprietary technology platform that enables specific regulation of gene expression and gene modification. The basis of this platform is a naturally occurring class of transcription factors, zinc finger DNA-binding proteins (ZFPs) which we can engineer to drive desired therapeutic outcomes.
Psyadon Pharmaceuticals is dedicated to the discovery and development of new treatments for the serious psychiatric and neurological diseases. Ecopipam,their first development candidate, selectively blocks the actions of the neurotransmitter dopamine at the D1 subtype in the brain. Psyadon Pharmaceuticals, Inc. was formerly known as Ruxton Pharmaceuticals, Inc. and changed its name in 2008. The company was founded in 2004 and is based in Germantown, Maryland.
Cardioxyl Pharmaceuticals mission is the discovery and development of new classes of safe and effective therapeutic agents for the treatment of cardiovascular disease.
Johns Hopkins Technology Transfer
100 North Charles Street
Baltimore, MD 21201
Phone: (410) 516-8300